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Asthma as a cell mediated immune response Our understanding of the pathology of asthma has altered in the last 10 years and this has been reflected in changes in clinical management.' 2 At the cellular level asthma was previously regarded as a classical type I hypersensitivity reaction of Gell and Coombs, with IgE triggered release of mast cell mediators leading to the intermittent bronchoconstriction which characterises the disease.3 While such mechanisms should not be overlooked and may contribute to mortality in atopic subjects,4 it is difficult to explain all features of the disease, in particular intrinsic or some forms of occupational asthma, on this basis. Post mortem studies of patients dying from asthma identified a significant mononuclear cell and eosinophil infiltration in the bronchial mucosa. 56 The application of fibreoptic bronchoscopy to the study of asthma has revealed that an inflammatory infiltrate is present in the bronchial mucosa, even in those with mild asthma and no current symptoms.7-1' Eosinophil granule cationic proteins such as major basic protein (MBP) and eosinophil cationic protein (ECP) will lead to damage to bronchial epithelium in vitro at concentrations detected in vivo.8 [12] [13] [14] It is suggested that these products may contribute to the observed epithelial damage in the airways in asthma, and that these changes (in addition to the actions of eosinophil lipid mediators such as platelet activating factor and leukotriene C4) may contribute to the bronchial hyperresponsiveness to non-specific inhaled stimuli that is now included in the definition of asthma.2 13 15 Eosinophil infiltration and activation in biopsy samples of bronchial mucosa and bronchoalveolar lavage fluid is also detected in intrinsic and occupational asthma. [16] [17] [18] [19] Recent evidence is thus of a cellular immune response with eosinophil activation as a final common pathway in atopic and non-atopic forms of asthma. This may determine the bronchial hyperresponsiveness which predisposes to bronchoconstriction in these different manifestations of the disease, with an additional and possibly separate contribution from IgE dependent mechanisms in those with atopic asthma.
Cytokines
Lymphokines were originally defined as cell free soluble factors generated by sensitised lymphocytes in response to specific antigen. 20 The terms cytokine and interleukin broaden the definition to factors originating from many different cell types.2' 22 Cytokines were defined initially on the basis of their actions, but the cloning of the genes for these products greatly enhanced classification and cytokine expression in vivo can now be studied at the gene, messenger RNA, or protein level.22 Identification of cytokine genes has also allowed examination of factors regulating production of different cytokines. 23 It is the aim of this review to examine the role of different cytokines in determining the nature of the airway inflammatory response in asthma, and to outline briefly the in vitro, animal, and human studies suggesting which cytokines may be important. Rather than cataloguing the vast array of cytokines present, this article will focus on the importance of particular cytokines and how this adds to our knowledge of the actions of currently available therapeutic agents such as corticosteroids, and on cytokine targets for future more specific asthma treatment.
CYTOKINES RELEVANT and IL-4 are mast cell growth factors in rodents, they do not appear to be active in human mast cell proliferation and the role of stem cell factor (SCF) in human mast cell activity in asthma remains to be defined. 57 The role of neutrophils in asthma is uncertain: although these cells are present after experimental allergen challenge and neutrophil chemoattractants distinct from IL-8 have been isolated,58-60 increased numbers are not seen in bronchial biopsy specimens or bronchoalveolar lavage fluid from patients with non-acute asthma.8"1 Deposition of collagen below the bronchial basement membrane is described in asthma6' although the significance is unknown. Profibrogenic cytokines such as transforming growth factor fi (TGF-/J) or platelet derived growth factor ,B
(PDGF-f6) may be implicated,6' and both of these cytokines may influence T cell responses (see below). 63 64 Although a bewildering array of different cytokines may be involved in asthma, the important specific cytokines thus appear to be IL-5 (with IL-3 and GM-CSF) in eosinophil activation, and IL-4 in IgE regulation in atopic disease. Clearly other cytokines are implicated and, while targeting single mediators may be of value, an understanding of the cell(s) of origin and control of cytokine synthesis in asthma will be essential to future therapeutic intervention.
Patterns of T cell cytokine response which may determine immunopathology Interaction of a specific T cell receptor with an antigen peptide complexed with major histocompatibility products on antigen presenting cells is the principal initiating event in specific immune responses leading to immunoglobulin synthesis or cellular activation.6566 In vitro and animal studies have defined the pivotal role of T lymphocyte and T cell derived cytokines in the control of eosinophil differentiation and activation and IgE synthesis.'7'86768 There is now considerable evidence for activation of Th lymphocytes (CD4 +) in asthma (table 2). TGF-f) and PDGF-fl inhibit Th2 cytokine production in the murine system.63 64 The local cytokine microenvironment may thus contribute to the nature of the T cell response, which in turn may determine the type of cellular response which follows. 80 If 
Evidence for involvement of cytokines in asthma STABLE MILD ASTHMA Sera and peripheral blood T cell culture supematants from subjects with asthma were shown to support eosinophil survival in vitro. 90 The serum activity was inhibited by antibodies to IL-5 and GM-CSF but not to IL-3, whereas the T cell supernatant activity appeared to be principally GM-CSF and was derived from the CD4 + subset (with no activity from CD8 + T cells). Detection of cytokine protein in bronchoalveolar lavage fluid is hampered by the sensitivity of currently available assays, and the problems of variable dilution of the epithelial lining fluid by instilled saline. However, IL-4 and IL-5 were detected in 18-21 fold concentrated bronchoalveolar lavage fluid from subjects with atopic asthma by immunoenzymatic and bioassay respectively, whereas IL-2 and IFNy were present in much lower concentrations. (median forced expiratory volume in one second (FE1V) 82% predicted, and methacholine PC2, 0-6 mg/ml) and asymptomatic seasonal asthmatic subjects (median FEVI 103%, PC20 10-4 mg/ml) showed increased expression of mRNA for IL-3, IL-4, IL-5, and GM-CSF in those with symptoms, but no differences between the groups in cells expressing IL-2 or IFNy mRNA.94 Furthermore, relationships were observed between proportions of IL-4 and IL-5 mRNA positive cells in bronchoalveolar lavage fluid and both airway obstruction and bronchial responsiveness. Broide and coworkers detected increased concentrations of TNFa, GM-CSF, and I-6 in bronchoalveolar lavage fluid from symptomatic asthmatic subjects (mean FEVy 59% predicted) when compared with asymptomatic subjects (FEV1 86%), whereas IL-2 and IL-lfl were detected in equal quantities in both groups. 95 Interleukin-1 a and IL-4 were not detected in bronchoalveolar lavage fluid from asthmatic subjects in this study although, unlike the previously described reports, the study group included patients receiving a wide range of medications and corticosteroids were given to those with symptoms before the study.
There is little information on cytokines in intrinsic asthma. Concentrated bronchoalveolar lavage fluid from intrinsic asthmatic subjects showed detectable quantities of IL-2 and IL-5 but, in contrast to atopic subjects in the same study, IL-4 was not detected.'9 ACUTE SEVERE ASTHMA Sera from subjects admitted to hospital with acute severe asthma had detectable concentrations of IFNy which correlated with FEV, and decreased as patients responded to corticosteroid therapy. 96 24 hours after allergen or diluent control challenge in mild atopic asthmatic subjects. There was a significant increase in the number of eosinophils and CD4 + T cell activation after allergen challenge, and this was accompanied by increased numbers of cells in the fluid positive for IL-4, IL-5, and GM-CSF mRNA. There was no difference in numbers of cells in the bronchoalveolar lavage fluid expressing IL-2, IL-3, or IFNy mRNA when allergen and diluent control challenge were compared.'03 Interleukin-5 was detected by immunoenzymatic assay in bronchoalveolar lavage fluid obtained 48 hours after local instillation of allergen into the airways of non-asthmatic atopic subjects and this was associated with an increase in the number of eosinophils. 104 Effects of corticosteroids on cy-tokines in asthma Corticosteroid therapy reduces symptoms and bronchial responsiveness and improves lung function in asthma.'05 Corticosteroids are now widely used as anti-inflammatory treatment in asthma, in accordance with current guidelines.'06107 In vitro studies suggest that corticosteroids act to inhibit cytokine production.'08-1"0 Is there evidence for such a role in vivo in asthma? Inhaled corticosteroids reduced eosinophil infiltration and activation in bronchoalveolar lavage fluid and bronchial biopsy samples in asthma, and T cell numbers in bronchial biopsy samples were reduced."1-"13 Oral prednisolone treatment was associated with a reduction in serum IFNyin acute severe asthma, and serum IL-5 fell to undetectable concentrations after one week of prednisolone treatment in subjects with exacerbations of their disease. 97 We have recently studied the effects of two weeks of oral prednisolone treatment on eosinophils, T cell activation and cytokine mRNA expression in bronchoalveolar lavage fluid in a double blind placebo controlled study in symptomatic asthma. When subjects receiving prednisolone were compared with those treated with placebo, a significant fall in bronchial responsiveness was associated with a fall in eosinophils in the bronchoalveolar lavage fluid. Furthermore, this was associated with a significant reduction in the proportion of cells in the fluid expressing mRNA for IL-4 and IL-5, whereas there was an increase in IFNy mRNA positive cells."14 Thus corticosteroid therapy in asthma was associated with modulation of cytokine gene expression. Cyclosporin A is a potent inhibitor of T cell IL-2 gene expression in vitro, with well defined specific molecular targets."'' This agent produced a significant improvement in steroid dependent asthmatic subjects, possibly reflecting actions on cytokine gene expression."6 
initiation and maintenance of eosinophilic bronchial inflammation in asthma, and suggests that successful treatment is associated with inhibition of IL-5 production. Evidence from animal experiments also supports a pivotal role for IL-5 in asthma (table 3) . Interleukin-4, unopposed by IFNy, may be important in atopic asthma.
An important question remains. Which cell types are responsible for production of cytokines in the airway in asthma? Although IL-4 and IL-5 were initially described as T cell products, other cell types may produce these and other cytokines. Murine mast cell lines can produce IL-3, IL-4, IL-5, TNFa, and GM-CSF,"7-"9 and human cells of mast/basophil lineage are also capable of cytokine synthesis. 120 Alveolar macrophages from asthmatic subjects spontaneously produce GM-CSF in vitro.'2' More recently in vitro production of several cytokines by eosinophils (IL-3,122 IL-5,123 IL-6,'24 IL-8,125 GM-CSF126), and bronchial epithelial cells (GM-CSF, IL-8) has been reported. 127 Messenger RNA for GM-CSF and IL-5 was localised to eosinophils, in addition to mononuclear cells, in bronchoalveolar lavage fluid obtained after local allergen challenge of atopic asthmatic subjects. ' 
